Cargando…

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency

INTRODUCTION: Alpha-1 antitrypsin (AAT) deficiency (AATD) is associated with early onset emphysema. The aim of this study was to investigate whether AAT binding to plasma constituents could regulate their activation, and in AATD, exploit this binding event to better understand the condition and unco...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Brien, Michael E, Fee, Laura, Browne, Niall, Carroll, Tomás P, Meleady, Paula, Henry, Michael, McQuillan, Karen, Murphy, Mark P, Logan, Mark, McCarthy, Cormac, McElvaney, Oliver J, Reeves, Emer P, McElvaney, Noel G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Respiratory Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231451/ https://www.ncbi.nlm.nih.gov/pubmed/31959730 http://dx.doi.org/10.1136/thoraxjnl-2019-214076

Ejemplares similares

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
por: McQuillan, Karen, et al.
Publicado: (2020)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Altered Degranulation and pH of Neutrophil Phagosomes Impacts Antimicrobial Efficiency in Cystic Fibrosis
por: Hayes, Elaine, et al.
Publicado: (2020)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application
por: O’Brien, Michael E., et al.
Publicado: (2022)

C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency
por: Fee, Laura T., et al.
Publicado: (2021)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences
por: Lavelle, Gillian M., et al.
Publicado: (2016)

In vitro and in vivo modulation of NADPH oxidase activity and reactive oxygen species production in human neutrophils by α(1)-antitrypsin
por: Hawkins, Padraig, et al.
Publicado: (2021)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets
por: Vega-Carrascal, Isabel, et al.
Publicado: (2012)

Hypertonic Saline in Treatment of Pulmonary Disease in Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2012)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

The Involvement of Glycosaminoglycans in Airway Disease Associated with Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2011)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
por: McElvaney, Oliver J., et al.
Publicado: (2022)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
por: O’Shea, Orlagh, et al.
Publicado: (2023)

Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
por: White, Michelle M., et al.
Publicado: (2017)

The importance of CFTR expression for neutrophil function in patients with Cystic Fibrosis
por: Jundi, B, et al.
Publicado: (2015)

Adult and Adolescent Disclosures of Child Sexual Abuse: A Comparative Analysis
por: McGill, Lucy, et al.
Publicado: (2022)

Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
por: Caird, Robin, et al.
Publicado: (2022)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
por: McElvaney, Oisin F., et al.
Publicado: (2022)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation
por: Ma, Shuren, et al.
Publicado: (2019)

A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2020)

Corrigendum to ‘A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19’
por: McElvaney, Oliver J, et al.
Publicado: (2020)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB
por: Hassan, Tidi, et al.
Publicado: (2017)

Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients
por: Palmas, Francesco, et al.
Publicado: (2021)

Perceiving threat in others: The role of body morphology
por: McElvaney, Terence J., et al.
Publicado: (2021)

Identifying criminals: No biasing effect of criminal context on recalled threat
por: McElvaney, Terence J., et al.
Publicado: (2022)

Prone positioning improves oxygenation and lung recruitment in patients with SARS-CoV-2 acute respiratory distress syndrome; a single centre cohort study of 20 consecutive patients
por: Clarke, Jennifer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rat69n6lhvbb6372o5nspsb39o